While the FDA has been in the news for a handful of approvals over the past year-plus, New York dermatologist Bruce Katz, MD, and his colleagues, are “beyond excited” for the administration’s upcoming consent in the field of aesthetics.
Enter DAXI, a neuromodulator that Dr. Katz explains is “like Botox, except it lasts longer, with a time span averaging around 24 weeks.”
What it means: “Patients only need about two treatments per year to maintain their results,” he says.
While this latest, longer-lasting offering isn’t necessarily designed to replace other injectables, Dr. Katz gives it a thumb’s up mainly because it gives patients a “different option” when it comes to wrinkle-relaxers.
